Background {#Sec1}
==========

Human trichomoniasis, caused by *Trichomonas vaginalis*, is the most widespread non-viral sexually transmitted infection, with approximately 276 million cases reported annually worldwide \[[@CR1]\]. *Trichomonas vaginalis* infects both women and men, although 89% of trichomoniasis patients are women as a result of their higher occurrence of symptoms \[[@CR2]\]. Men are often asymptomatic carriers of *T. vaginalis* infection, although dysuria, discharge and increased risk of infertility and prostate cancer have been reported \[[@CR3]\]. Infected women may develop vaginitis, urethritis and cervicitis, potentially leading to serious health outcomes, such as infertility, preterm delivery, low-birth-weight infants, susceptibility to herpes simplex virus and human papillomavirus infection, and cervical cancer \[[@CR4]\]. Trichomoniasis has been associated with an increased risk of human immunodeficiency virus (HIV) transmission \[[@CR5]\].

In addition to the symptoms and signs, direct microscopic examination, including the wet mount test and Pap smear test, and traditional culture are the most common diagnostic methods for *T. vaginalis* infection. Moreover, rapid antigen detection and nucleic acid amplification test are also used for *T. vaginalis* diagnosis \[[@CR6]\].

Current treatments for trichomoniasis include a single oral dose of metronidazole (MTZ; 2 g), a single oral dose of tinidazole (2 g), or a 7-day oral course of MTZ (500 mg twice daily) \[[@CR7]\]. The prevalence of trichomoniasis varies among different subpopulations, ranging from 5.4% in family planning clinics and 17.3% in patients presenting to sexually transmitted disease clinics, to 32% among incarcerated women \[[@CR8], [@CR9]\]. The prevalence of *T. vaginalis* in women with recurrent urinary tract infections in Taiwan was 16.9% \[[@CR10]\]. However, no large-scale epidemiological study of trichomoniasis in Taiwan has been conducted. Hence, it is necessary to understand the prevalence of trichomoniasis for women in Taiwan to improve their sexual and reproductive health.

Psychiatric disorders, also called mental disorders, are defined as clinically significant behavioral or psychological syndromes, with a high level of individual distress, anxiety and premature mortality \[[@CR11]\]. In the USA, the regional disease burden attributable to mental disorders, neurological disorders, substance use disorders and self-harm comprises 19% of total disability-adjusted life-years and 34% of total years lived with disability in 2015 \[[@CR12]\]. Mental health problems thereby represent important public health challenges worldwide. There is a growing interest in the role of microbes, such as viruses and protozoan parasites, in some psychiatric disorders \[[@CR13]--[@CR15]\]. For instance, several studies have shown impaired cognitive functions among individuals with schizophrenia exposed to neurotropic herpes simplex virus type 1 \[[@CR16]\]. Additionally, it has been reported that prenatal maternal exposure to influenza, rubella, genital-reproductive infections and other pathogens are associated with schizophrenia and autism \[[@CR17], [@CR18]\]. The protozoan parasite *Toxoplasma gondii* is an extensively studied candidate that is associated with various psychiatric disorders, such as schizophrenia \[[@CR19], [@CR20]\]. Having a neurotropic nature and brain-damaging characteristic, *T. gondii* is a potential causative agent for mental and behavioral disorders \[[@CR14]\]. However, there is limited evidence for the association of other protists and psychiatric disorders, especially those whose colonization sites are not directly linked to the central nervous system.

Recently, we observed an unexpected trend that trichomoniasis patients were accompanied by some psychiatric disorders in the Tri-Service General Hospital, raising the possibility that there is an association between *T. vaginalis* infection and the risk of psychiatric disorders. Hence, we conducted a nationwide population-based cohort study to verify whether *T. vaginalis* infection may lead to psychiatric disorders. Our findings underscore the potential risk of *T. vaginalis* for developing psychiatric disorders, providing a novel and clinically important role of this neglected protozoan parasite.

Methods {#Sec2}
=======

Data sources {#Sec3}
------------

The National Health Insurance (NHI) programme began in Taiwan in 1995 and covers more than 99% of entire population, with approximately 23 million beneficiaries \[[@CR21]\]. The data were collected from the NHI Research Database (NHIRD) of Taiwan. The NHRID uses the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) codes to record diagnoses \[[@CR22]\]. A subset of the NHIRD, the Longitudinal Health Insurance Database 2000 (LHID 2000), was utilized to investigate the association between trichomoniasis and psychiatric disorders. The LHID 2000 provided a million individuals randomly selected from the entire NHI enrollee population in the year 2000. The ICD-9-CM codes of trichomoniasis-related diagnoses were included in the study group, such as trichomonal vulvovaginitis (ICD-9-CM 131.01), trichomonal urethritis (ICD-9-CM 131.02), other urogenital trichomoniasis (ICD-9-CM 131.09), trichomoniasis of other specified sites (ICD-9-CM 131.8) and unspecified trichomoniasis (ICD-9-CM 131.9). Detailed information of the ICD-9-CM codes used in this study is provided in Additional file [1](#MOESM1){ref-type="media"}: Table S1.

Study design and population {#Sec4}
---------------------------

The patients newly diagnosed with trichomoniasis were selected from the LHID 2000 from 1st January 2000 to 31st December 2013. The following criteria were excluded: (i) patients with trichomoniasis before the index date; (ii) patients with psychiatric disorders before tracking; (iii) patients younger than 18 years of age; and (iv) gender is male or unknown. Ultimately, a total of 9373 subjects with trichomoniasis were included in the study group. The non-trichomoniasis control group (37,492 individuals) was established by matching the age and index year with a 4-fold ratio to the study group.

Covariates {#Sec5}
----------

We examined the sociodemographic factors in the study and control groups, including age, monthly income, season, place of residence, urbanization level and hospital level. The patients were classified into three groups based on age: 18--44 years; 45--64 years; and ≥ 65 years. The monthly income in New Taiwan Dollars (NTD) was divided into three groups: \<18,000; 18,000--34,999; and ≥35,000. Four seasons (spring, summer, autumn and winter) were considered. The patients living in different areas of Taiwan, including northern, middle, southern, and eastern Taiwan, as well as the outlets islands were compared. The patients were categorized into four urbanization levels from the highest (1) to the lowest (4). Three levels for hospitals where the patients sought medical attention were considered: medical centers; regional hospitals; and local hospitals.

Main outcome measures {#Sec6}
---------------------

All study participants were followed from the index date until the onset of all recorded psychiatric disorders in the NHIRD. The incidences and risk of each individual psychiatric disorder, including depression, anxiety, bipolar disorder, schizophrenia and substance abuse, were compared between the study group and the control group. The incidences and risk for overall and subgroups of psychiatric disorders in the trichomoniasis patients treated with MTZ were compared with the untreated trichomoniasis patients and the non-trichomoniasis group.

Statistical analysis {#Sec7}
--------------------

All statistical analyses were performed using SPSS software v.22.0 (SPSS, Chicago, IL, USA). A Chi-square test was used to analyze the categorical variables. Fisher's exact test was used to evaluate the differences between the study and control groups. Differences in the risk of psychiatric disorders in the study and control groups were evaluated using the Kaplan-Meier method with a log-rank test and presented as a survival curve. Cox proportional hazards regression analysis was used to determine the risk of psychiatric disorder, and the data were expressed as aHR with a 95% confidence interval (CI).

Results {#Sec8}
=======

Demographic characteristics of the study population at the baseline and endpoint {#Sec9}
--------------------------------------------------------------------------------

Based on propensity score matching (the ratio of the study population to the control population was 1:4), there were 9373 individuals with trichomoniasis in the study group and 37,492 individuals without trichomoniasis in the control group (Fig. [1](#Fig1){ref-type="fig"}). The demographic characteristics of the study and control populations at the baseline are described in Table [1](#Tab1){ref-type="table"}. There was no significant difference in age between the control and study groups (42.06 ± 16.09 *vs* 42.09 ± 16.71). The percentage of the population whose monthly income less than NTD \$18,000 in the study group was significantly higher than the control group (98.13 *vs* 88.15%; *P* \< 0.001). Compared with the control population, the study population had more medical visits in summer (26.51 *vs* 23.95%; *P* \< 0.001), with a higher proportion of patients living in eastern Taiwan (14.04 *vs* 4.35%; *P* \< 0.001). Regarding the medical care system, more patients with trichomoniasis sought medical help in regional hospitals as compared to the non-trichomoniasis group (49.89 *vs* 29.59%; *P* \< 0.001). The demographic characteristics of the study and control populations at the tracking endpoint are described in Additional file [2](#MOESM2){ref-type="media"}: Table S2. Except the difference in age between the study and control groups (45.49 ± 19.64 *vs* 46.85 ± 17.85; t-test, *P* \< 0.001), all the trends of characteristics between trichomoniasis subjects and non-trichomoniasis subjects were similar to those observed at the baseline.Fig. 1Flowchart of study and control subject's collection from the Longitudinal Health Insurance Database, a subset of the National Health Insurance Research Database (NHIRD) of Taiwan. The subjects were tracked from 2000 to 2013 Table 1Demographic characteristics of the study and control populations at the baselineCharacteristicTotalWithWithout*P-*value^a^*n*%*n*%*n*%Total46,865937320.0037,49280.00Age (years)42.08 ± 16.5942.06 ± 16.0942.09 ± 16.710.889Age group (years)0.999 18--4428,35060.49567060.4922,68060.49 45--6413,61529.05272329.0510,89229.05 ≥ 65490010.4698010.46392010.46Insured premium (NT\$)\<0.001 \< 18,00042,24890.15919898.1333,05088.15 18,000--34,99932216.871541.6430678.18 ≥ 35,00013962.98210.2213753.67CCI0.48 ± 1.400.61 ± 1.460.45 ± 1.39\<0.001Season\<0.001 Spring (March-May)12,19426.02238025.39981426.18 Summer (June-August)11,46624.47248526.51898123.95 Autumn (September-November)11,24223.99221223.60903024.09 Winter (December-February)11,96325.53229624.50966725.78Location\<0.001 Northern Taiwan18,55039.58324134.5815,30940.83 Middle Taiwan13,40528.60247826.4410,92729.14 Southern Taiwan11,77425.12233124.87944325.19 Eastern Taiwan29476.29131614.0416314.35 Outlets islands1890.4070.071820.49Urbanization level\<0.001 1 (The highest)16,14234.44234525.0213,79736.80 220,16043.02474650.6315,41441.11 338158.146306.7231858.50 4 (The lowest)674814.40165217.63509613.59Level of care\<0.001 Hospital center14,32930.58286330.5511,46630.58 Regional hospital15,77133.65467649.8911,09529.59 Local hospital16,76535.77183419.5714,93139.82^a^Chi-square/Fisher's exact test on categorical variables and t-test on continuous variables*Abbreviation*: CCI, Charlson comorbidity index

Association of trichomoniasis with psychiatric disorders {#Sec10}
--------------------------------------------------------

The incidences of psychiatric disorders were higher for study subjects with trichomoniasis (875 subjects, 9.34%) than control subjects (1988 subjects, 5.3%) (*P* \< 0.001) (Table [2](#Tab2){ref-type="table"}). Additionally, Kaplan-Meier analysis for the cumulative risk of psychiatric disorders during 14 years of follow-up showed a statistical difference in the study group compared with the control group (log-rank *P* \< 0.001), and this difference began from the first year of tracking (Fig. [2](#Fig2){ref-type="fig"}). The medium duration from the diagnosis of *T. vaginalis* infection to the onset of overall psychiatric disorder was 2.17 years. Additionally, the medium duration from the diagnosis of *T. vaginalis* infection to the onset of individual psychiatric disorder ranged between 0.79--2.34 years (Additional file [3](#MOESM3){ref-type="media"}: Table S3). Furthermore, the incidences for the subgroups of the psychiatric disorders were significantly higher in the subjects with trichomoniasis than in the control group, including depression (3.96 *vs* 2.17%; *P* \< 0.001), anxiety (3.14 *vs* 1.47%; *P* \< 0.001), bipolar disorder (0.45 *vs* 0.28%; *P* = 0.011), schizophrenia (0.97 *vs* 0.39%; *P* \< 0.001), substance abuse (0.9 *vs* 0.24%; *P* \< 0.001) and other psychiatric disorders (0.82 *vs* 0.15%; *P* \< 0.001). The risk of psychiatric disorders in subjects with trichomoniasis was analyzed by Cox regression and presented as adjusted hazard ratio (aHR), with reference to the non-trichomoniasis group (Table [3](#Tab3){ref-type="table"}). The trichomoniasis patients showed a higher risk of overall psychiatric disorders, with an aHR of 1.644 (95% CI: 1.514--1.766; *P* \< 0.001).Table 2Incidence of psychiatric disorders in the trichomoniasis patients compared with the control groupVariableTotalWithWithout*P*-value^a^*n*%*n*%*n*%Total46,8659,37320.0037,49280.00Psychiatric disorders\<0.001 Without44,00293.89849890.6635,50494.70 With28636.118759.3419885.30Depression\<0.001 Without45,68297.48900296.0436,68097.83 With11832.523713.968122.17Anxiety\<0.001 Without46,01898.19907996.8636,93998.53 With8471.812943.145531.47Bipolar disorders0.011 Without46,71899.69933199.5537,38799.72 With1470.31420.451050.28PTSD/ASD0.375 Without46,81699.90936699.9337,45099.89 With490.1070.07420.11Schizophrenia\<0.001 Without46,62799.49928299.0337,34599.61 With2380.51910.971470.39Substance abuse\<0.001 Without46,69099.63928999.1037,40199.76 With1750.37840.90910.24Other psychiatric disorders\<0.001 Without46,73299.72929699.1837,43699.85 With1330.28770.82560.15^a^Chi-square/Fisher's exact test on categorical variables and t-test on continuous variables*Abbreviation*: PTSD, post-traumatic stress disorder; ASD, acute stress disorder Fig. 2Kaplan-Meier curves for cumulative risk of psychiatric disorders stratified by trichomoniasis with the log-rank test. The numbers of psychiatric disorders in the patients with trichomoniasis and the non-trichomoniasis group are shown during the 14 years of follow-up Table 3Risk of psychiatric disorders in the trichomoniasis subjects identified by using Cox regressionVariableAdjusted HR95% CI*P*-valueWithout trichomoniasisReferenceWith trichomoniasis1.6441.514--1.766\<0.001*Abbreviations*: Adjusted HR, adjusted hazard ratio (adjusted for the variables listed in Table [1](#Tab1){ref-type="table"}); CI, confidence interval

Risk of psychiatric disorders in the trichomoniasis group stratified by covariates {#Sec11}
----------------------------------------------------------------------------------

The risk of psychiatric disorders in the trichomoniasis group stratified by variables was further evaluated (Table [4](#Tab4){ref-type="table"}). Except for level of medical care, almost all study subjects kept the higher risk of developing psychiatric disorders irrespective of being stratified by independent variables. Specifically, the trichomoniasis patients stratified by the different age groups revealed that the subjects aged 45--64 years had the highest risk (aHR = 2.637; *P* \< 0.001) compared with the non-trichomoniasis control. Additionally, study subjects which had a monthly income of less than NTD \$18,000 (aHR = 1.669; *P* \< 0.001) were associated with a higher risk of psychiatric disorders. Furthermore, patients with the lowest urbanization level (level 4) (aHR = 3.814; *P* \< 0.001) had a markedly increased risk of psychiatric disorders.Table 4Risk of psychiatric disorders in the trichomoniasis subjects stratified by variables using Cox regressionStratifiedWith *vs* without trichomoniasisAdjusted HR95% CI*P*-valueTotal1.6441.514--1.766\<0.001Age group (years) 18--441.1551.017--1.3120.027 45--642.6372.325--2.991\<0.001 ≥ 650.9230.696--1.2240.577Insured premium (NT\$) \< 18,0001.6691.536--1.813\<0.001 18,000--34,9990.000--0.937 ≥ 35,0000.000--0.986Season Spring1.5511.307--1.841\<0.001 Summer2.3092.010--2.651\<0.001 Autumn1.1100.906--1.3600.314 Winter1.4281.195--1.706\<0.001Urbanization level 1 (the highest)1.8031.596--2.037\<0.001 21.4281.209--1.688\<0.001 31.2911.074--1.5520.007 4 (the lowest)3.8142.752--5.285\<0.001Level of care Hospital center1.4791.315--1.664\<0.001 Regional hospital1.5941.354--1.877\<0.001 Local hospital2.0111.693--2.389\<0.001*Abbreviations*: Adjusted HR, adjusted hazard ratio (adjusted for the variables listed in Table [1](#Tab1){ref-type="table"}); CI, confidence interval; NT\$, New Taiwan Dollars

Reduced risk for the subgroups of psychiatric disorders in the trichomoniasis subjects following MTZ treatment {#Sec12}
--------------------------------------------------------------------------------------------------------------

The risk of the main subgroups of psychiatric disorders in trichomoniasis patients was examined (Table [5](#Tab5){ref-type="table"}). Compared with the non-trichomoniasis group, trichomoniasis subjects had a higher risk of substance abuse (aHR = 2.794; 95% CI: 2.035--3.834; *P* \< 0.001), anxiety (aHR = 2.011; 95% CI: 1.738--2.327; *P* \< 0.001), schizophrenia (aHR = 1.981; 95% CI: 1.495--2.624; *P* \< 0.001), bipolar disorders (aHR = 1.784; 95% CI: 1.241--2.565; *P* \< 0.001) and depression (aHR = 1.675; 95% CI: 1.474--1.904; *P* \< 0.001). There was no statistical significance in the risk of post-traumatic stress disorder or acute stress disorder (PTSD/ASD) and other psychiatric disorders between the trichomoniasis and non-trichomoniasis groups.Table 5Risk of psychiatric disorders subgroup in the trichomoniasis patients treated with MTZ identified by using Cox regressionPsychiatric disorder subgroupTrichomoniasis and metronidazole (MTZ)Competing risk in the modelPopulationEventAdjusted HR95% CI*P*Adjusted HR95% CI*P*Adjusted HR95% CI*P*OverallWithout trichomoniasis37,492198Ref.Ref.With trichomoniasis93738751.6441.514--1.766\<0.001 With trichomoniasis, without MTZ64336301.7321.577--1.902\<0.001Ref. With trichomoniasis, with MTZ29402451.4581.271--1.672\<0.0010.8760.739--1.0390.128DepressionWithout trichomoniasis37,492812Ref.Ref. With trichomoniasis93733711.6751.474--1.904\<0.001 With trichomoniasis, without MTZ64332661.8651.613--2.156\<0.001Ref.With trichomoniasis, with MTZ29401051.3351.083--1.6470.0070.6390.493--0.8290.001AnxietyWithout trichomoniasis37,492553Ref.Ref.With trichomoniasis93732942.0111.738--2.327\<0.001 With trichomoniasis, without MTZ64332312.1201.807--2.486\<0.001Ref. With trichomoniasis, with MTZ2940631.7011.301--2.222\<0.0010.9480.692--1.3000.741Bipolar disorderWithout trichomoniasis37,492105Ref.Ref.With trichomoniasis9373421.7841.241--2.5650.002 With trichomoniasis, without MTZ6433352.2191.497--3.287\<0.001Ref. With trichomoniasis, with MTZ294070.9080.418--1.9720.8070.4810.207--1.1180.089PTSD/ASDWithout trichomoniasis37,49242Ref.Ref.With trichomoniasis937370.7920.354--1.7720.570 With trichomoniasis, without MTZ643371.0150.450--2.2880.972Ref. With trichomoniasis, with MTZ294000.0001--0.9630.0001--0.971SchizophreniaWithout trichomoniasis37,492147Ref.Ref.With trichomoniasis9373911.9811.495--2.624\<0.001 With trichomoniasis, without MTZ6433702.3151.699--3.156\<0.001Ref. With trichomoniasis, with MTZ2940211.3520.838--2.1800.2160.6900.385--1.2370.212Substance abuseWithout trichomoniasis37,49291Ref.Ref.With trichomoniasis9373842.7942.035--3.834\<0.001 With trichomoniasis, without MTZ6433562.972.073--4.256\<0.001Ref. With trichomoniasis, with MTZ2940282.5161.615--3.919\<0.0010.9780.428--2.6860.057Other psychiatric disordersWithout trichomoniasis37,49256Ref.Ref.With trichomoniasis9373771.0980.872--1.2110.184 With trichomoniasis, without MTZ6433491.0120.642--1.190.872Ref. With trichomoniasis, with MTZ2940281.5841.104--1.9840.0011.9711.169--3.3220.011*Abbreviations*: MTZ, metronidazole; Adjusted HR, adjusted hazard ratio (adjusted for the variables listed in Table [1](#Tab1){ref-type="table"}); CI, confidence interval; PTSD, post-traumatic stress disorder; ASD, acute stress disorder; Ref., reference

The risk for the subgroups of psychiatric disorders in the trichomoniasis subjects treated with MTZ was examined compared with the non-trichomoniasis group and the trichomoniasis subjects without MTZ treatment (Table [5](#Tab5){ref-type="table"}). The trichomoniasis subjects treated with MTZ had a lower risk of developing bipolar disorder and schizophrenia than the trichomoniasis subjects without MTZ treatment, with aHRs of 0.908 (95% CI: 0.418--1.972; *P* = 0.807) and 1.352 (95% CI: 0.838--2.180; *P* = 0.216), respectively, with no statistical difference between the MTZ-treated group and the non-trichomoniasis control. Although MTZ treatment had a lower risk for developing several subgroups of psychiatric disorders with reference to the untreated trichomoniasis subjects, significant reduction was detected for depression only (aHR = 0.639; 95% CI: 0.493--0.829; *P* = 0.001).

Increased risk of psychiatric disorders in subjects with refractory trichomoniasis {#Sec13}
----------------------------------------------------------------------------------

It is estimated that approximately 5--10% of trichomoniasis patients display resistance to drug treatment \[[@CR23], [@CR24]\]. We also evaluated the risk for psychiatric disorders in the trichomoniasis subjects who sought medical help more than once (Table [6](#Tab6){ref-type="table"}). Compared with the non-trichomoniasis group, the risk for overall psychiatric disorders in subjects with trichomoniasis was proportional to the number of medical visits. Except for bipolar disorder and PTSD/ASD, refractory trichomoniasis patients (trichomoniasis visits ≥2) had a higher risk for the other psychiatric disorders (*P \< *0.001) compared with the patients who sought medical help only once.Table 6Risk of psychiatric disorders subgroup among study population and trichomoniasis cohort identified by using Cox regressionPsychiatric disorders subgroupTrichomoniasis visitsStudy populationTrichomoniasis cohortPopulationEventAdjusted HR95% CI*P*Adjusted HR95% CI*P*Overall0 (without trichomoniasis)37,4921988Ref.1 trichomoniasis visit90518092.5602.353--2.784\<0.001Ref.≥ 2 trichomoniasis visits322667.6765.953--9.898\<0.0012.6642.047--3.467\<0.001Depression037,492812Ref.190513412.7122.381--3.089\<0.001Ref.≥ 2322308.3065.667--12.173\<0.0012.5941.741--3.866\<0.001Anxiety037,492553Ref.190512712.9752.562--3.454\<0.001Ref.≥ 23222310.6746.853--16.623\<0.0013.4722.199--5.482\<0.001Bipolar disorder037,492105Ref.19051422.6791.854--3.873\<0.001Ref.≥ 232200.000--0.968\<0.0001--0.972PTSD/ASD037,49242Ref.1905171.0130.456--2.2980.978Ref.≥ 232200.000--0.988\<0.0001--0.989Schizophrenia037,492147Ref.19051843.9492.992--5.212\<0.001Ref.≥ 2322712.4715.739--27.101\<0.0012.8061.260--6.2470.012Substance abuse037,49291Ref.19051801.5351.301--2.011\<0.001Ref.≥ 232243.8972.049--7.122\<0.0013.2861.870--5.864\<0.001Other psychiatric disorders037,49256Ref.19051661.8621.503--2.188\<0.001Ref.≥ 2322115.8973.402--9.864\<0.0015.6422.864--7.862\<0.001*Abbreviations*: Adjusted HR, adjusted hazard ratio (adjusted for the variables listed in Table [1](#Tab1){ref-type="table"}); CI, confidence interval; PTSD, post-traumatic stress disorder; ASD, acute stress disorder; Ref., reference

Association of trichomoniasis with other sexually transmitted infections {#Sec14}
------------------------------------------------------------------------

It has been shown that *T. vaginalis* infection was associated with other sexually transmitted infections (STIs), such as *Chlamydia trachomatis*, *Neisseria gonorrhoeae*, *Treponema pallidum* and HIV \[[@CR25]--[@CR27]\]. Our data indicated that 3.03% of the subjects with trichomoniasis were co-infected with *N. gonorrhoeae* or *T. pallidum*, 0.61% co-infected with *N. gonorrhoeae* or *C. trachomatis*, and 0.12% co-infected with *T. pallidum* or *C. trachomatis* (Additional file [4](#MOESM4){ref-type="media"}: Table S4). Combined analysis revealed that 13.99% of subjects with trichomoniasis were co-infected with one of these three common STIs (*N. gonorrhoeae*, *T. pallidum* or *C. trachomatis*). Additionally, a total of 12 trichomoniasis subjects were infected with HIV, whereas 4 non-trichomoniasis subjects were infected with HIV (Additional file [5](#MOESM5){ref-type="media"}: Table S5). Among the trichomoniasis subjects, 5 and 3 subjects were infected with HIV before and after the index date, respectively. For the non-trichomoniasis subjects, 1 and 2 cases were infected with HIV before and after the index date, respectively. All HIV-positive patients were treated.

Discussion {#Sec15}
==========

The trichomoniasis subjects enrolled in this study had a higher risk of overall psychiatric disorders, with an aHR of 1.644, as compared with the non-trichomoniasis control. This means that patients with trichomoniasis had a 1.644-fold increased risk for developing psychiatric disorders. The Kaplan-Meier analysis also supported the cumulative risk for psychiatric disorders in the trichomoniasis subjects during 14 years of follow-up (log-rank *P* \< 0.001). More specifically, the trichomoniasis subjects had a significantly increased risk of depression, anxiety, bipolar disorder, schizophrenia and substance abuse. These results highlight the novel role of *T. vaginalis* in causing psychiatric disorders, and that clinicians should pay more attention to the possible risk resulting from this neglected tropical disease.

Previous studies have reported that some psychiatric disorders are associated with inflammatory diseases, such as periodontitis \[[@CR28]\], psoriasis \[[@CR29]\] and allergic diseases\[[@CR30]\]. The underlying mechanism of this association is possibly due to the release of pro-inflammatory cytokines, such as interleukin (IL)-6, IL-10, tumor necrosis factor alpha, and monocyte chemoattractant protein-1, which have been proved to be involved in the development of depression, anxiety and bipolar disorders. *Trichomonas vaginalis* infection has been shown to induce IL-8 secretion from primary human monocytes \[[@CR31]\] and the symbiotic relationship with *Mycoplasma hominis* enables induction of an array of inflammatory cytokines in a macrophage cell line \[[@CR32]\]. In addition to causing local inflammation, *T. vaginalis* also induces systemic immune response in infected pregnant women, resulting in higher concentrations of granulocyte-macrophage colony-stimulating factor and C-reactive protein in serum of patients \[[@CR33]\]. Further investigation is needed to clarify whether the *T. vaginalis*-induced immune response plays a role in developing psychiatric disorders.

Another possibility is that a behavioral pathway may link *T. vaginalis* infection and the risk of psychiatric disorders. For instance, women with *T. vaginalis* infection might present many vaginal symptoms that may affect their sexual life. Their partners might be annoyed with the diagnoses which can complicate their sexual relationship. Therefore, these problems associated with difficulties in getting cured might increase anxiety and other common mental disorders. Additionally, it has been reported that there is an association between high-risk sexual behaviors and sexually transmitted diseases in patients with psychiatric disorders \[[@CR34]\]. Thus, the higher *T. vaginalis* infection in psychiatric patients may alternatively have resulted from high-risk sexual behaviors of patients during their prodromal stage.

We found that trichomoniasis subjects aged 45--64 years had a higher risk of psychiatric disorders than those aged 18--44 years. Since the maximal follow-up time is 14 years, we proposed that a certain portion of the trichomoniasis population aged 18--44 years may not reach the age of onset for most major psychiatric disorders \[[@CR35]\]. Another possible reason for this observation may be due to the menopausal transition, a period late in a woman's reproductive life before the final menstruation, typically occurring between the ages of 40 and 55 years. Previous studies demonstrated that women with symptomatic menopausal transition may have a higher risk for developing subsequent psychiatric disorders, especially depression \[[@CR36]\], anxiety \[[@CR37]\] and bipolar disorder \[[@CR38]\], thereby enhancing the risk in the trichomoniasis subjects.

Mental disorders contribute to 7% of the global burden of disease as estimated by disability adjusted life years in the world; this is rising, especially in low- and middle-income countries \[[@CR39]\]. Low income has been demonstrated to be directly linked with psychiatric disorders \[[@CR40]\]. Indeed, we have revealed that the trichomoniasis subjects with a monthly income less than NTD \$18,000 were associated with a higher risk of psychiatric disorders.

Although MTZ treatment for the trichomoniasis patients had a lower risk for developing overall psychiatric disorders, the differences between the treated and untreated groups was not statistically significant. Specifically, MTZ treatment was remarkably associated with a decreased risk of bipolar disorder and schizophrenia, suggesting that *T. vaginalis* infection is closely related with these two psychiatric disorders. Additionally, MTZ treatment was associated with a lower risk for developing depression as compared with the untreated group. Based on these findings, it is likely that trichomoniasis may directly or indirectly involve the process of development for specific psychiatric disorders. Furthermore, increasing reports of failures in the treatment of trichomoniasis and the rising prevalence of MTZ-resistant *T. vaginalis* isolates have occurred \[[@CR23], [@CR41], [@CR42]\]. Hence, the differences in treatment outcomes of patients due to drug resistance may also influence the risk for developing psychiatric disorders. Indeed, our further analysis of the trichomoniasis subjects who sought medical help more than once (≥ 2 times) had a higher risk for psychiatric disorders, which is likely caused by drug resistance. Our data revealed that 68.6% patients with trichomoniasis were not treated. A recent study in Belgium demonstrated that 58.1% of women repeatedly positive for *T. vaginalis* infection had received no treatment; this was attributed to low awareness, poor attention, and failure of contact tracing of physicians \[[@CR43]\].

One of the major strengths of this study is its large-scale population-based nationwide design. Additionally, the long-term monitoring from 2000 to 2013 made the analysis more reliable. However, the study has several limitations. First, the diagnoses were made using ICD-9 codes recorded in the NHIRD, but this database does not contain all types of data, such as laboratory parameters and genetic factors, which may help to postulate the mechanisms mediating the development of psychiatric disorders in patients with trichomoniasis. Secondly, although men were not included in the study, they potentially transmit the infection to women through sexual behavior and affect the treatment outcomes for women. Hence, sexual partners have to be treated to enhance the treatment efficiency. Thirdly, *T. vaginalis* infection is largely neglected because of ineffective screening protocols and a lack of public health attention \[[@CR44]\]. The exact number of patients with trichomoniasis must be higher than those who seek medical attention, and thereby the cases of psychiatric disorders resulted from *T. vaginalis* infection must be underestimated.

Conclusions {#Sec16}
===========

To our knowledge, we provide the first evidence that *T. vaginalis* infection is associated with the risk of overall psychiatric disorders. The potential role of trichomoniasis in the devolvement of psychiatric disorders will highlight its clinical importance and public health impact. Clinicians should pay more attention to this neglected pathogen, which not only results in urogenital symptoms, but also leads to psychiatric disorders, especially in patients with refractory trichomoniasis.
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aHR

:   adjusted hazard ratio

CI

:   confidence interval

HR

:   hazard ratio

HIV

:   human immunodeficiency virus

IL

:   interleukin

LHID 2000

:   Longitudinal Health Insurance Database 2000

MTZ

:   metronidazole

NHI

:   National Health Insurance

NHIRD

:   National Health Insurance Research Database

NTD

:   New Taiwan Dollars

PTSD

:   post-traumatic stress disorder

ASD

:   acute stress disorder
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